The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
Open accessAbstract
BACKGROUND: Entecavir is a potent and selective guanosine analogue with significant activity against hepatitis B virus (HBV). METHODS: In this phase 3, double-blind trial, we randomly assigned 715 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had not previously received a nucleoside analogue to receive either 0.5 mg of entecavir or 100 mg of lamivudine once daily for a minimum of 52 weeks. The primary efficacy end point was histologic improvement (a decrease by at least two points in the Knodell necroinflammatory score, without worsening of fibrosis) at week 48. Secondary end points included a reduction in the serum HBV DNA level, HBeAg loss and seroconversion, and normalization of the alanine aminotransferase level. RESULTS: Histologic improvement after 48 weeks occurred in 226 of 314 patients in the entecavir group (72 percent) and 195 of 314 patients in the lamivudine group (62 percent, P=0.009). More patients in the entecavir group than in the lamivudine group had undetectable serum HBV DNA levels according to a polymerase-chain-reaction assay (67 percent vs. 36 percent, P<0.001) and normalization of alanine aminotransferase levels (68 percent vs. 60 percent, P=0.02). The mean reduction in serum HBV DNA from baseline to week 48 was greater with entecavir than with lamivudine (6.9 vs. 5.4 log [on a base-10 scale] copies per milliliter, P<0.001). HBeAg seroconversion occurred in 21 percent of entecavir-treated patients and 18 percent of those treated with lamivudine (P=0.33). No viral resistance to entecavir was detected. Safety was similar in the two groups. CONCLUSIONS: Among patients with HBeAg-positive chronic hepatitis B, the rates of histologic, virologic, and biochemical improvement are significantly higher with entecavir than with lamivudine. The safety profile of the two agents is similar, and there is no evidence of viral resistance to entecavir. (ClinicalTrials.gov number, NCT00035633.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Cited by
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Self-citationTelbivudine versus Lamivudine in Patients with Chronic Hepatitis B
Lai, C.-L., Gane, E., Liaw, Y.-F., Hsu, C.-W., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, E. J., Rasenack, J., Bzowej, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066422 · Cited by 773
Self-citationJones, J., Shepherd, J., Baxter, L., Gospodarevskaya, E., Hartwell, D., Harris, P., & Price, A. (2009) · Health Technology Assessment · doi:10.3310/hta13350 · Cited by 357
Side effects of long-term oral antiviral therapy for hepatitis B
Fontana, R. J. (2009) · Hepatology · doi:10.1002/hep.22885 · Cited by 272
Zeisel, M. B., Lucifora, J., Mason, W. S., Sureau, C., Beck, J., Levrero, M., Kann, M., Knolle, P. A., Benkirane, M., Durantel, D., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-308943 · Cited by 256
Metadata
- Authors
- Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., Cross, A., DeHertogh, D., Wilber, R., Colonno, R., & Apelian, D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-09
- Volume
- 354
- Issue
- 10
- Pages
- 1001-1010
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1985860298
- Cited by
- 1,444
- References
- 1
- FWCI
- 100.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. https://app.cochat.ai/papers/10.1056/nejmoa051285
- The paper
- Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., Cross, A., DeHertogh, D., Wilber, R., Colonno, R., & Apelian, D. (2006). A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. New England Journal of Medicine. https://doi.org/10.1056/nejmoa051285
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
